Recombinant |
Dual PA anthrax-LcrV-F1 plague nanoparticle T4 phage delivery system |
Mice rats and rabbits |
Complete protection against both lethal challenges of inhalation anthrax and pneumonic plague |
Tao et al. 2018
|
Y. pseudotuberculosis expressing the Y. pestis F1 antigen |
Mice |
Protection against both bubonic and pneumonic challenge, and serum transfer to naïve mice protected against bubonic challenge; protection against challenge with F1 variant |
Demeure et al. 2017, 2019a, b
|
Oral Y. pseudotuberculosis ΔyopK ΔyopJ Δasd + Y. pestis fusion protein (truncated YopE1-138-LcrV |
Mouse |
Conferred 80% and 90% survival against bubonic and pneumonic challenge; strong humoral and CMI responses; protection against lethal Y. enterocolitica and Y. pseudotuberculosis challenge |
Singh et al. 2019
|
Y. pestis KIM ΔyopJ overexpressing the Y. enterocolitica YopP |
OF1 mice |
Protection against pneumonic and bubonic challenge and against Y. enterocolitica challenge and Francisella tularensis challenge |
Zauberman et al. 2013
|
Lactobacillus plantarum expressing LvrV-F1 and Tobacco Mosaic Virus (TMV) expressing LcrV-F1 |
Mouse |
TMV LcrV-F1 provided 100% protection against a pneumonic plague challenge; L. plantarum LcrV-F1 conferred only partial protection |
Arnaboldi et al. 2016
|
Salmonella expressing LcrV, F1 and pesticin receptor (Psn) |
Mouse |
Oral immunization, conferred 100% protection against both bubonic and pneumonic plague |
Sananpala et al. 2016 |
Francisella tularensis ΔcapB + F1-LcrV and a multiple-gene-deleted Listeria monocytogenes vaccine strain, + F1-LcrV |
Mouse |
Following a prime-boost schedule with both platforms, mice were protected against pneumonic plague challenge |
Jia et al. 2018
|
Live-attenuated vaccines |
EV vaccine efficacy measure |
Humans (Kazakhstan) |
Highest level of protective anti-F1 serum antibodies was observed 4 months following vaccination with significant reduced antibody titers at both 8 and 12 months |
Sagiyev et al. 2019
|
EV plague vaccine strain |
Humans |
Robust cell-mediated responses to Pla protease in immunized humans for up to 1 year following vaccination |
Feodorova et al. 2018
|
Y. pestis subspecies: altaica 1-2948/3, 1-3749, and 1/3480 |
Mouse |
Elicit strong cell-mediated responses |
Balakhonov et al. 2017
|
Y. pestis EV vaccine strain and the microtus 201 (avirulent in humans) strain |
Rhesus macaques (intravenous (i.v.) infection model) |
The microtus strain infected monkey lungs and led to 100% mortality in 1010 i.v.-challenged animals; none of the EV-challenged animals died at that same dose |
Tian et al. 2014
|
Rodent |
Sylvatic plague vaccine (SPV), a virally vectored bait system vaccine |
Wild prairie dogs |
Capture of unique prairie dogs on vaccine-treated fields was significantly higher in each of the 2 years tested on 29 paired plots of land in 7 Western US states years tested |
Rocke et al. 2017
|
SPV |
Wild prairie dogs |
Bait uptake of the SPV vaccine, during a 3-year study, was as high as 70% over 58 plots of land; heavier animals exhibited increased bait uptake; baiting later in the growing season influenced bait uptake |
Abbott et al. 2018
|
SPV |
Wild prairie dogs |
In two of the three plots evaluated, both pesticide dusting and oral SPV improved prairie dog survival |
Trip et al. 2017 |
SPV |
Wild prairie dogs and non-target rodents |
70% of the bait-based vaccine was consumed by non-target rodents over a 3-year period in which no effects were observed |
Bron et al. 2018
|
LMA and LMP live-attenuated vaccines |
Mice and rats |
100% efficacy during bubonic and pneumonic plague (short- and ling-term), generate robust humoral and cell-mediated immune responses |
Tiner et al. 2015a, b, 2016; Van Lier et al. 2014, 2015
|